<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516123</url>
  </required_header>
  <id_info>
    <org_study_id>CS3006-101</org_study_id>
    <nct_id>NCT03516123</nct_id>
  </id_info>
  <brief_title>A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, dose escalation &amp; expansion phase I study to evaluate the&#xD;
      clinical safety, tolerability, PK, and preliminary efficacy of CS3006.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS3006</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>CS3006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CS3006 orally at specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS3006</intervention_name>
    <description>In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.&#xD;
In the dose expansion part, participants will receive CS3006 at specified dose level(s).</description>
    <arm_group_label>CS3006</arm_group_label>
    <other_name>MEK inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with histologically or cytologically confirmed advanced or metastatic solid&#xD;
             tumor(s) for which no effective standard therapy is available or tolerable.&#xD;
&#xD;
          2. ECOG performance status of 0 or 1.&#xD;
&#xD;
          3. Life expectancy â‰¥12 weeks.&#xD;
&#xD;
          4. Able to swallow and retain oral medication.&#xD;
&#xD;
          5. Subjects must have adequate organ function.&#xD;
&#xD;
          6. Use of effective contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects receiving anti-cancer therapy at the time of enrollment.&#xD;
&#xD;
          2. Subjects who had prior chemotherapy, targeted therapy, immunotherapy or any other&#xD;
             systemic anti-cancer treatment, within 14 days prior to the first dose of CS3006 or&#xD;
             who has not recovered from adverse events due to a prior therapy.&#xD;
&#xD;
          3. Receipt of any prior therapy with a MEK inhibitor.&#xD;
&#xD;
          4. Use of any investigational anti-cancer drug within 28 days before the first dose of&#xD;
             CS3006.&#xD;
&#xD;
          5. Current use of a prohibited medication or use during treatment of CS3006.&#xD;
&#xD;
          6. Current use of warfarin.&#xD;
&#xD;
          7. Any condition that will interfere significantly with the absorption, distribution,&#xD;
             metabolism, or excretion of drugs.&#xD;
&#xD;
          8. History of retinal vein occlusion (RVO) or central serous retinopathy (CSR).&#xD;
&#xD;
          9. Visible retinal pathology as assessed by ophthalmologic exam.&#xD;
&#xD;
         10. Intraocular pressure &gt; 21mm Hg as measured by tomography.&#xD;
&#xD;
         11. Glaucoma diagnosed within one month prior to the first dose of CS3006.&#xD;
&#xD;
         12. Known brain metastasis or other CNS metastasis that is either symptomatic or&#xD;
             untreated.&#xD;
&#xD;
         13. Primary malignancy of CNS.&#xD;
&#xD;
         14. Evidence of severe or uncontrolled systemic diseases.&#xD;
&#xD;
         15. Subjects with clinically significant cardiovascular disease.&#xD;
&#xD;
         16. QTc interval &gt;= 450 msecs for male or &gt;= 470 msecs for female&#xD;
&#xD;
         17. Known history of HIV.&#xD;
&#xD;
         18. Subjects with active Hepatitis B or C infection&#xD;
&#xD;
         19. History of immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to CS3006.&#xD;
&#xD;
        For more information regarding trial participation, please contact at&#xD;
        cstonera@cstonepharma.com&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Huang</last_name>
    <role>Study Director</role>
    <affiliation>CStone Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>January 9, 2021</last_update_submitted>
  <last_update_submitted_qc>January 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

